The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

Inclusion Criteria: * Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy. * Women of reproductive potential must have a negative serum pregnancy test at the study screening visit. * Patients must give written informed consent to participate in the study. * Patients must be able to take oral medication. * Patients should be completely recovered from recent surgery. * Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. * Patients must be evaluated by the radiation oncologist prior to study entry. Exclusion Criteria: * Extensive Stage SCLC. * Women who are pregnant or lactating. * Use of an investigational drug within 30 days prior to the first dose of study medication. * Any medically/clinically significant active infection. * Symptoms of the SCLC spreading to the brain. * Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy. * Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk. * Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.